mesenchymal stem cells

Oncology

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.

News

Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.